This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

NCT05438810 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

312

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer
Female Breast Cancer

Interventions

DRUG: FCN-437c,Fulvestrant,Goserelin acetate
DRUG: Placebo,Fulvestrant,Goserelin acetate

Sponsor

Ahon Pharmaceutical Co., Ltd.